ONEOK's fee-based model, strong yield, and growth catalysts offer stability and upside in a volatile market. See why OKE ...

Bristol Myers Squibb is making progress paying down debt from prior deals and improving financial flexibility so it can make ...

Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.